These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

489 related items for PubMed ID: 27590328

  • 1. Sarcoidosis-like syndrome and lymphadenopathy due to checkpoint inhibitors.
    Firwana B, Ravilla R, Raval M, Hutchins L, Mahmoud F.
    J Oncol Pharm Pract; 2017 Dec; 23(8):620-624. PubMed ID: 27590328
    [Abstract] [Full Text] [Related]

  • 2. Immune checkpoint blocker-related sarcoid-like granulomatous inflammation: a rare adverse event detected in lymph node aspiration cytology of patients treated for advanced malignant melanoma.
    Rodriguez EF, Lipson E, Suresh K, Cappelli LC, Monaco SE, Maleki Z.
    Hum Pathol; 2019 Sep; 91():69-76. PubMed ID: 31279873
    [Abstract] [Full Text] [Related]

  • 3. Delayed onset of neurosarcoidosis after concurrent ipilimumab/nivolumab therapy.
    Tan I, Malinzak M, Salama AKS.
    J Immunother Cancer; 2018 Jul 31; 6(1):77. PubMed ID: 30064495
    [Abstract] [Full Text] [Related]

  • 4. Drug-induced sarcoidosis-like reaction in adjuvant immunotherapy: Increased rate and mimicker of metastasis.
    Chorti E, Kanaki T, Zimmer L, Hadaschik E, Ugurel S, Gratsias E, Roesch A, Bonella F, Wessendorf TE, Wälscher J, Theegarten D, Schadendorf D, Livingstone E.
    Eur J Cancer; 2020 May 31; 131():18-26. PubMed ID: 32248071
    [Abstract] [Full Text] [Related]

  • 5. Immunotherapy-associated autoimmune hemolytic anemia.
    Khan U, Ali F, Khurram MS, Zaka A, Hadid T.
    J Immunother Cancer; 2017 May 31; 5():15. PubMed ID: 28239468
    [Abstract] [Full Text] [Related]

  • 6. The emerging use of immune checkpoint blockade in the adjuvant setting for solid tumors: a review.
    Moujaess E, Haddad FG, Eid R, Kourie HR.
    Immunotherapy; 2019 Nov 31; 11(16):1409-1422. PubMed ID: 31621445
    [Abstract] [Full Text] [Related]

  • 7. Prognostic factors and outcomes in metastatic uveal melanoma treated with programmed cell death-1 or combined PD-1/cytotoxic T-lymphocyte antigen-4 inhibition.
    Heppt MV, Heinzerling L, Kähler KC, Forschner A, Kirchberger MC, Loquai C, Meissner M, Meier F, Terheyden P, Schell B, Herbst R, Göppner D, Kiecker F, Rafei-Shamsabadi D, Haferkamp S, Huber MA, Utikal J, Ziemer M, Bumeder I, Pfeiffer C, Schäd SG, Schmid-Tannwald C, Tietze JK, Eigentler TK, Berking C.
    Eur J Cancer; 2017 Sep 31; 82():56-65. PubMed ID: 28648699
    [Abstract] [Full Text] [Related]

  • 8. Immune checkpoint inhibitor-associated sarcoidosis: A usually benign disease that does not require immunotherapy discontinuation.
    Chanson N, Ramos-Casals M, Pundole X, Suijkerbuijk K, José de Barros E Silva M, Lidar M, Benesova K, Leipe J, Acar-Denizli N, Pradère P, Michot JM, Voisin AL, Suárez-Almazor ME, Radstake TRD, Fernandes Moça Trevisani V, Schulze-Koops H, Melin A, Robert C, Mariette X, Baughman RP, Lambotte O, ICIR, Coordination, Co-Convenors, Steering Committee, Research Fellows, Data Scientist.
    Eur J Cancer; 2021 Nov 31; 158():208-216. PubMed ID: 34452793
    [Abstract] [Full Text] [Related]

  • 9. Management of Adverse Events Following Treatment With Anti-Programmed Death-1 Agents.
    Weber JS, Postow M, Lao CD, Schadendorf D.
    Oncologist; 2016 Oct 31; 21(10):1230-1240. PubMed ID: 27401894
    [Abstract] [Full Text] [Related]

  • 10. Thrombocytopenia in patients with melanoma receiving immune checkpoint inhibitor therapy.
    Shiuan E, Beckermann KE, Ozgun A, Kelly C, McKean M, McQuade J, Thompson MA, Puzanov I, Greer JP, Rapisuwon S, Postow M, Davies MA, Eroglu Z, Johnson D.
    J Immunother Cancer; 2017 Oct 31; 5():8. PubMed ID: 28239462
    [Abstract] [Full Text] [Related]

  • 11. Intralesional and systemic immunotherapy for metastatic melanoma.
    Luu C, Khushalani NI, Zager JS.
    Expert Opin Biol Ther; 2016 Dec 31; 16(12):1491-1499. PubMed ID: 27602429
    [Abstract] [Full Text] [Related]

  • 12. Sarcoidosis Following Anti-PD-1 and Anti-CTLA-4 Therapy for Metastatic Melanoma.
    Reddy SB, Possick JD, Kluger HM, Galan A, Han D.
    J Immunother; 2017 Oct 31; 40(8):307-311. PubMed ID: 28737620
    [Abstract] [Full Text] [Related]

  • 13. Sarcoidosis post-anti-PD-1 therapy, mimicking relapse of metastatic melanoma in a patient undergoing complete remission.
    Yatim N, Mateus C, Charles P.
    Rev Med Interne; 2018 Feb 31; 39(2):130-133. PubMed ID: 29277453
    [Abstract] [Full Text] [Related]

  • 14. Side effect management during immune checkpoint blockade using CTLA-4 and PD-1 antibodies for metastatic melanoma - an update.
    Kähler KC, Hassel JC, Heinzerling L, Loquai C, Thoms KM, Ugurel S, Zimmer L, Gutzmer R, committee on “Cutaneous Adverse Events“ of the German Working Group for Dermatological Oncology (Arbeitsgemeinschaft Dermatologische Onkologie, ADO).
    J Dtsch Dermatol Ges; 2020 Jun 31; 18(6):582-609. PubMed ID: 32489011
    [Abstract] [Full Text] [Related]

  • 15. Immunotherapy-induced sarcoidosis in patients with melanoma treated with PD-1 checkpoint inhibitors: Case series and immunophenotypic analysis.
    Lomax AJ, McGuire HM, McNeil C, Choi CJ, Hersey P, Karikios D, Shannon K, van Hal S, Carr U, Crotty A, Gupta SK, Hollingsworth J, Kim H, Fazekas de St Groth B, McGill N.
    Int J Rheum Dis; 2017 Sep 31; 20(9):1277-1285. PubMed ID: 28480561
    [Abstract] [Full Text] [Related]

  • 16. The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.
    Mahoney KM, Freeman GJ, McDermott DF.
    Clin Ther; 2015 Apr 01; 37(4):764-82. PubMed ID: 25823918
    [Abstract] [Full Text] [Related]

  • 17. A new frontier in treatment of advanced melanoma: Redefining clinical management in the era of immune checkpoint inhibitors.
    Levine O, Devji T, Xie F.
    Hum Vaccin Immunother; 2017 Aug 03; 13(8):1765-1767. PubMed ID: 28481695
    [Abstract] [Full Text] [Related]

  • 18. [Not Available].
    Mateus C, Libenciuc C, Robert C.
    Bull Cancer; 2016 Jun 03; 103(6 Suppl 1):S4-S11. PubMed ID: 27494973
    [Abstract] [Full Text] [Related]

  • 19. Immune Checkpoint Inhibitors: New Insights and Current Place in Cancer Therapy.
    La-Beck NM, Jean GW, Huynh C, Alzghari SK, Lowe DB.
    Pharmacotherapy; 2015 Oct 03; 35(10):963-76. PubMed ID: 26497482
    [Abstract] [Full Text] [Related]

  • 20. Predictors of immunotherapy-induced immune-related adverse events.
    Kartolo A, Sattar J, Sahai V, Baetz T, Lakoff JM.
    Curr Oncol; 2018 Oct 03; 25(5):e403-e410. PubMed ID: 30464691
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 25.